ErepoXen (polysialylated erythropoietin) / Xenetic Biosci, Serum Institute of India, Pharmsynthez - LARVOL DELTA

Xenetic Biosciences News: Why XBIO Stock Is Going Ballistic Today (Nasdaq) - "Xenetic Biosciences (NASDAQ:XBIO) news for Wednesday includes positive news from a Phase 3 clinical trial boosting XBIO stock higher....XBIO stock was up 418.5% as of Wednesday morning."

P3 data • Stock price • Renal Disease

Xenetic Biosciences: Annual Report 2015 (Xenetic Biosciences) - Anticipated data from P2a PSA-EPO-03 trial in anemia in Q2 2016; Anticipated final data from second cohort of P2 trial in CKD in H1 2016

Anticipated P2 data • Anticipated P2a data • Biosimilar

Xenetic Biosciences: Investor Presentation (Xenetic Biosciences) - "ErepoXen was in general well tolerated. There was 1 Significant Adverse Event possibly related to ErepoXen in this cohort"; "9 of 14 patients were clear responders reaching therapeutic hemoglobin levels in 4 to 6 weeks"

P2 data • Biosimilar

Xenetic Biosciences: Investor Presentation (Xenetic Biosciences) - Anticipated top-line results from P2 study for anemia in chronic kidney disease in October 2016

Anticipated P2 data • Biosimilar

Xenetic Biosciences: Q3 FY 2016 Results (Xenetic Biosciences) - Anticipated top-line data from fourth and fifth cohorts of P2 dose-escalation trial in pre-dialysis CKD anemia in 2017

Anticipated P2 data • Biosimilar

Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in Healthcare Facilities: A Systematic Review and Reanalysis of Quasi-experimental Studies. (PubMed, Clin Infect Dis) - "Among all CRE-CRAB-CRPsA EPOC studies, the most frequent intervention components included contact precautions (90%), active surveillance cultures (80%), monitoring, audit and feedback of measures (80%), patient isolation or cohorting (70%), hand hygiene (50%), and environmental cleaning (40%); nearly all studies with these interventions reported a significant reduction in slope and/or level. The quality of EPOC studies was very low to low."

Journal • Review